Microalbuminuria and cardiorenal risk: old and new evidence in different populations
作者: Diego Francisco MárquezGema Ruiz-HurtadoJulian SeguraLuis Ruilope
作者单位: 1Unidad de Hipertensión Arterial-Servicio de Clínica Médica, Hospital San Bernardo, Salta, Argentina
2Instituto de Investigación Imas12 and Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain
3Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma, Madrid, Spain
4Escuela de Estudios Postdoctorales and Investigación, Universidad de Europa de Madrid, Madrid, Spain
刊名: F1000Research, 2019, Vol.8
来源数据库: F1000 Research Ltd
DOI: 10.12688/f1000research.17212.1
关键词: AlbuminuriaCardiovascular riskChronic kidney disease
原始语种摘要: Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has...
全文获取路径: F1000 Research Ltd 

  • cardiorenal 心肾的
  • hypertensive 高血压的
  • angiotensin 血管紧张肽
  • evidence 
  • converting 转换
  • hypertension 高血压
  • diabetes 糖尿病
  • albuminuria 蛋白尿
  • blocker 间苗器
  • determination 测定